JPMorgan Chase & Co’s Phathom Pharmaceuticals PHAT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.33M | Buy |
138,516
+1,123
| +0.8% | +$10.8K | ﹤0.01% | 3587 |
|
|
2025
Q1 | $861K | Buy |
137,393
+486
| +0.4% | +$3.05K | ﹤0.01% | 3739 |
|
|
2024
Q4 | $1.11M | Buy |
136,907
+1,476
| +1% | +$12K | ﹤0.01% | 3732 |
|
|
2024
Q3 | $2.45M | Buy |
135,431
+1,074
| +0.8% | +$19.4K | ﹤0.01% | 3128 |
|
|
2024
Q2 | $1.38M | Sell |
134,357
-4,095
| -3% | -$42.2K | ﹤0.01% | 3315 |
|
|
2024
Q1 | $1.47M | Sell |
138,452
-7,585
| -5% | -$80.6K | ﹤0.01% | 3339 |
|
|
2023
Q4 | $1.33M | Buy |
146,037
+1,281
| +0.9% | +$11.7K | ﹤0.01% | 3367 |
|
|
2023
Q3 | $1.5M | Buy |
144,756
+10,760
| +8% | +$112K | ﹤0.01% | 3180 |
|
|
2023
Q2 | $1.92M | Buy |
133,996
+409
| +0.3% | +$5.86K | ﹤0.01% | 3066 |
|
|
2023
Q1 | $954K | Buy |
133,587
+4,438
| +3% | +$31.7K | ﹤0.01% | 3473 |
|
|
2022
Q4 | $1.45M | Sell |
129,149
-42,221
| -25% | -$474K | ﹤0.01% | 3164 |
|
|
2022
Q3 | $1.9M | Buy |
171,370
+583
| +0.3% | +$6.46K | ﹤0.01% | 2955 |
|
|
2022
Q2 | $1.44M | Sell |
170,787
-4,775
| -3% | -$40.3K | ﹤0.01% | 3242 |
|
|
2022
Q1 | $2.39M | Buy |
175,562
+3,001
| +2% | +$40.8K | ﹤0.01% | 3055 |
|
|
2021
Q4 | $3.39M | Buy |
172,561
+3,573
| +2% | +$70.3K | ﹤0.01% | 2836 |
|
|
2021
Q3 | $5.43M | Buy |
168,988
+156,643
| +1,269% | +$5.03M | ﹤0.01% | 2529 |
|
|
2021
Q2 | $418K | Sell |
12,345
-182,029
| -94% | -$6.16M | ﹤0.01% | 4099 |
|
|
2021
Q1 | $7.3M | Buy |
194,374
+7,368
| +4% | +$277K | ﹤0.01% | 2369 |
|
|
2020
Q4 | $6.21M | Buy |
187,006
+24,411
| +15% | +$811K | ﹤0.01% | 2267 |
|
|
2020
Q3 | $5.82M | Buy |
162,595
+2,476
| +2% | +$88.6K | ﹤0.01% | 2108 |
|
|
2020
Q2 | $5.27M | Buy |
160,119
+156,575
| +4,418% | +$5.15M | ﹤0.01% | 2118 |
|
|
2020
Q1 | $91K | Buy |
3,544
+35
| +1% | +$899 | ﹤0.01% | 3971 |
|
|
2019
Q4 | $109K | Buy |
+3,509
| New | +$109K | ﹤0.01% | 3995 |
|